Noninvasive Cancer Diagnostics Market
Corporate wellness programme managers
The holy grail of oncology is finding cancer early, before symptoms appear, when it is most curable. Traditional tissue biopsies are invasive, painful, and sometimes impossible depending on the tumour’s location. Noninvasive diagnostics, primarily liquid biopsies, detect fragments of tumour DNA (ctDNA) or circulating tumour cells (CTCs) floating in a simple blood draw. This technology is revolutionising how we monitor treatment response and detect recurrence. The emerging frontier is multi cancer early detection (MCED) tests that aim to screen healthy, asymptomatic populations for dozens of different cancer types from a single blood sample.
What Numbro covers:
Global market analysis of liquid biopsy by application: Therapy Selection (Companion Dx), Recurrence Monitoring (MRD), and Screening (MCED). Technology platform comparison: Next Generation Sequencing (NGS) based assays versus PCR based assays. Regulatory and reimbursement landscape analysis for novel screening tests (coverage by Medicare and private insurers). Clinical utility and cost effectiveness studies for population wide cancer screening programmes.
- Oncologists and clinical pathologists
- Diagnostic laboratory directors
- Health insurance and population health managers
- Employers designing executive health checkups
